Research programme: cell adhesion antagonists - ICOS

Drug Profile

Research programme: cell adhesion antagonists - ICOS

Alternative Names: Cell adhesion molecule antagonists research programme - ICOS

Latest Information Update: 24 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ICOS Corporation
  • Class Small molecules
  • Mechanism of Action Cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cardiovascular disorders; Fibrosis; Inflammation; Psoriasis

Most Recent Events

  • 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly
  • 10 Jul 2006 This programme is still in active development
  • 11 Dec 2003 Preclinical development for Fibrosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top